阻断泛素-蛋白酶体通路对人原代白血病细胞的作用

阻断泛素-蛋白酶体通路对不同类型细胞具有完全不同的结果, 但未见对原代白血病细胞作用的报道. 观察了阻断上述通路对8例白血病患者和10例正常人骨髓单个核细胞(MNC)的作用. 结果表明, 不同个体原代白血病细胞对阻断此通路的反应敏感性存在明显差异, 其中3例细胞极为敏感, 24 h以内90%细胞被迅速诱发凋亡, 而正常人骨髓MNC对阻断泛素蛋白酶体通路反应不敏感, 未观察到凋亡现象发生. 进一步的免疫印迹实验发现, 对上述通路敏感的原代白血病细胞Bcl-2蛋白表达量较高, 而且在凋亡过程中发生了特异位点的酶解;对上述通路不敏感的细胞(包括正常人骨髓MNC)Bcl-2蛋白低表达, 或Bcl-2高表达但未能检测到其特异性酶解现象. 结合其他实验结果, 提示细胞中Bcl-2蛋白是否发生特异位点酶解与细胞对阻断上述通路的敏感性之间具有相关性, 为进一步研究不同种类细胞对阻断泛素-蛋白酶体通路敏感性差异的机制提供了线索.     

用于FK506类小分子化合物筛选的细胞模型的建立

建立FKBP12/Fas双聚体可诱导细胞凋亡生物效应的细胞模型,为FK506类小分子化合药物的初步筛选提供一个可应用的技术平台.首先利用RT-PCR方法钓取人源性Fas胞浆区基因,测序鉴定正确后,插入到载体pC4M-FV2E中,构建pC4M-FV2E/Fas表达质粒.然后将Myr-FKBP12-Fas融合基因从pC4M-FV2E/Fas质粒克隆进pEGFP-N1中.最后将重组质粒pEGFP-N1/FKBP12-Fas转染进HEK293细胞,并利用G418筛选融合基因FKBP12-Fas稳定表达的细胞株.实验结果显示,阳性化合物AP20187作用4～6 h后,稳定转染的靶细胞发生凋亡,基因组呈现典型的“DNA Ladder”,而FKBP12的天然结合蛋白FK506可竞争性地阻断这种阳性药物诱导的细胞凋亡.研究提示：所构建的细胞模型,可用于以FKBP12为靶标、基于FK506空间构型设计合成的FK506类小分子化合药物的初步筛选.     

Effects of inhibition of ubiquitin-proteasome pathway on human primary leukemic cells

Though there were a lot of reports about the totally different responses to the inhibition of ubiquitin-proteasome pathway in different kinds of cell lines, much less has been known about the responses in primary human leukemic cells. In this study, the effects of inhibition of ubiq-uitin-proteasome pathway on human bone marrow (BM) mononuclear cells (MNCs) obtained from 10 normal persons and 8 leukemia patients were examined. The results showed that the responses obviously varied individually. Among them, BM MNCs in 3 cases of leukemic patients were extremely sensitive, demonstrated by that > 90% cells were induced to undergo apoptosis within 24 h, but MNCs in 10 cases of normal persons showed resistance to the inhibition and no apoptosis was observed. Furthermore, Western blots revealed that the Bcl-2 expression was relatively high in the sensitive primary leukemia cells, and especially the cleavage of 26 ku Bcl-2 into a 22 ku fragment occurred during the induction of apoptosis. In contrast, the Bcl-2 expression was either undetectable or detectable but no cleavage of that above was observed in the cells insensitive to the inhibition of the pathway (including BM MNCs in normal persons). Together with the observations on the leukemic cell lines, these findings suggested the correlation of the specific cleavage of Bcl-2 into a shortened fragment with the sensitivity of cells to the inhibition of ubiquitin-proteasome pathway, which provides clues to the further understanding of the mechanisms of that dramatically different responses existing in different kinds of cells to the inhibition of ubiq-uitin-proteasome pathway.     

SOX4单克隆抗体的制备及其在肿瘤细胞表达分析中的应用

应用分子生物学技术, 构建了含SOX4编码序列的原核表达载体, 在大肠杆菌 DH5a中获得了GST-SOX4融合蛋白的可溶性表达。应用谷胱甘肽-Sepharose 4B对重组蛋白进行了纯化, 利用纯化的融合蛋白免疫小鼠, 制备了可特异性识别SOX4的单克隆抗体。通过间接 ELISA 法鉴定了抗体的效价为1 × 10-5, Western blotting 分析证实了抗体的特异性。结果显示, 该抗体可识别细胞内外源性过表达及内源性的SOX4蛋白。在培养细胞系、小鼠不同组织中, SOX4蛋白的表达存在显著的差异。本研究制备的SOX4单克隆抗体具有良好的特异性, 为进一步研究SOX4在肿瘤发生中的作用提供了重要的工具。     

SOX11结合p53并上调其转录活性

目的:研究SOX11对p53转录活性的影响,并检测二者的体外相互作用。方法:在H1299(p53缺失)和H460(含野生型p53)2种细胞中分别过表达SOX11和p53,用双萤光素酶方法测定p53的转录活性;用大肠杆菌DH5α表达GST和GST-p53融合蛋白并将其纯化,用GST pull-down实验检测SOX11与p53在体外是否存在相互作用。结果:萤光素酶实验结果表明,在H1299和H460细胞中,过表达SOX11分别能促进外源p53和内源p53的转录活性;GST pull-down实验表明SOX11能在体外与p53发生相互作用。结论:SOX11能在体外与p53发生相互作用并促进p53的转录活性,为进一步研究p53的功能提供了新的线索。     

PD098059对IL-6诱导的M1细胞生长停止与终末分化的影响

 为探讨 IL- 6在 M1细胞中激活 Ras/MAPK通路的意义 ,以 MEK激酶的特异性抑制剂PD0 980 59阻断 Ras/MAPK通路的组成型激活及诱导激活 ,观测 PD0 980 59对 IL - 6诱导的 M1细胞生长停止及终末分化的影响 .发现 PD0 980 59可抑制 M1细胞的生长 ,并加强 IL- 6对 M1细胞的生长抑制效应 .PD0 980 59不影响 IL - 6诱导的 M1细胞形态改变及 CD1 1 b表达 ,但可显著降低 IL-6诱导的 M1细胞获得吞噬功能 .说明 Ras/MAPK途径的组成型激活及诱导激活是有重要意义的 ,它与 JAK- STATs途径既相互拮抗又相互协同 ,共同组成了 IL- 6对急性髓系白血病细胞生物学效应的精密调控作用 .     

CTLA4Ig融合蛋白在CHO细胞中的表达

CTLA4Ig是人CTLA4胞外区与人免疫球蛋白铰链区、CH2区、CH3区组成的融合蛋白,可以与B7结合,通过阻断B7与CD28的结合,从而阻断B7介导的T细胞活化必需的共刺激信号,可作为免疫抑制剂用于器官移植。将CTLA4Ig融合分子克隆到真核表达载体pCI-dhfr,并用脂质体方法转染到COS7和CHO-dhfr-细胞中,用氨甲喋呤筛选转染的CHO-dhfr-细胞。用RT-PCR、ELISA、细胞免疫荧光染色和Western-blot鉴定重组蛋白的表达。采用A蛋白纯化重组蛋白。     

低氧预处理对大鼠海马神经元缺氧耐受性和IL-1β表达的影响

目的:观察低氧预处理对大鼠海马神经元缺氧耐受性和白细胞介素- 1β(IL-1β)表达的影响.方法:取培养12 d的两组(对照组和低氧预处理组)培养神经元,同时置于缺氧环境(0.9L/LN2,0.1L/LCO2)中培养2、4、8和12 h. 分别观察它们的形态变化和神经元存活数,并用抗rhIL-1β单克隆抗体进行免疫组织化学染色,观察缺氧对大鼠海马培养神经元IL-1β表达的影响.结果:经低氧预处理的海马神经元缺氧后IL-1β表达较对照组减弱,神经元损伤程度减轻,神经元存活数明显高于对照组.结论:低氧预处理可使海马培养神经元对缺氧产生耐受 ,其中IL-1β表达降低可能是海马神经元对缺氧的一种适应性变化.     

抗人P185^erbB2的scFv—Fc融合蛋白的表达及免疫功能分析

为提高鼠源单抗用于体内治疗的效应功能及降低人抗鼠抗体反应 ,将编码抗人P185 erbB2 单抗轻、重链可变区 (VL、VH)融合构建的单链抗体 (scFv)基因片段与人IgG1的Fc区基因片段融合构建了scFv Fc融合基因 ,并将其克隆到哺乳动物细胞表达载体pCIDN中。用重组载体转染CHO细胞 ,通过G4 18筛选获得稳定高表达克隆。更换无血清培养基培养 ,经重组蛋白质A亲和层析柱纯化scFv Fc融合蛋白。融合蛋白质在还原SDS PAGE中表现为5 2kD的条带 ;与SK BR 3细胞裂解液共培育可特异性地沉淀出P185 erbB2 蛋白 ;FACS分析表明融合蛋白质识别P185 erbB2 蛋白的胞外段 ;ELISA测定融合蛋白质对细胞表面抗原P185 erbB2 的亲和常数为 7.5× 10 -10 (mol/L) -1。构建scFv Fc融合基因 ,将其克隆到表达载体 ,进一步稳定表达抗P185 erbB2 的scFv Fc融合蛋白 ,为进一步的体外、体内研究鼠源单抗治疗效果创造了条件。     

Effects of inhibition of ubiquitin-proteasome pathway on human primary leukemic cells

Though there were a lot of reports about the totally different responses to the inhibition of ubiquitin-proteasome pathway in different kinds of cell lines, much less has been known about the responses in primary human leukemic cells. In this study, the effects of inhibition of ubiquitin-proteasome pathway on human bone marrow (BM) mononuclear cells (MNCs) obtained from 10 normal persons and 8 leukemia patients were examined. The results showed that the responses obviously varied individually. Among them, BM MNCs in 3 cases of leukemic patients were extremely sensitive, demonstrated by that >90% cells were induced to undergo apoptosis within 24 h, but MNCs in 10 cases of normal persons showed resistance to the inhibition and no apoptosis was observed. Furthermore, Western blots revealed that the Bcl-2 expression was relatively high in the sensitive primary leukemia cells, and especially the cleavage of 26 ku Bcl-2 into a 22 ku fragment occurred during the induction of apoptosis. In contrast, the Bcl-2 e